Hologic

As of December 5, 2017, Hologic operates in the field of creating and supplying technologies for healthcare.

History of the company since 1960.

Performance indicators

2018: Losses of $111.3 million, revenue of $3.2 billion

In fiscal 2018, Hologic's revenue was $3.2 billion against $3.1 billion a year earlier. The reporting 12-month period ended on September 29, 2018 calendar.

The American manufacturer of mammography and X-ray equipment earned $2.6 billion from the sale of equipment and other products, while in 2017 these revenues were measured at $2.5 billion. Revenue from services and other sources of cash inflows Hologic rose on an annualized basis from $520.8 million to $574 million.

Hologic Revenue Change Dynamics

We ended the year clearly with a stronger position than we started as we improved the underlying growth in the largest divisions of Breast Health and Molecular Diagnostics. In addition, international sales continue to show steady growth, and we completed two attractive acquisitions that spurred the growth of the Breast Health business, "said Steve MacMillan, President, CEO and Chairman of the Board of Directors of Hologic.

Hologic sales outside the United States in 2018 amounted to $634 million, which is 13% higher than a year ago. The growth rate of international business is increasing. In 2017, revenue abroad increased by 11%, and in 2016 - there was a decline at all.

In the segment of diagnostic equipment, foreign revenue accounts for 23% of sales. In the segments of mammography and surgical technology, indicators are measured at 22% and 16%, respectively.

In 2018, the sales of Hologic diagnostic solutions were equal to $1.1 billion, which corresponds to 35.7% in total revenue. The share of mammographic products amounted to 37.9%, and their sales - $1.2 billion.

The 2018 fiscal year proved unprofitable for Hologic, with cash losses reaching $111.3 million. According to the results of the previous reporting year, the company received a net profit of $755.5 million.^[1]

History

2025: Investment companies Blackstone and TPG buy Hologic for $18.3 billion

American investment companies Blackstone and TPG Capital buy women's health technology developer Hologic with an enterprise value estimate (EV) of up to $18.3 billion. This was announced in October 2025 by Hologic. Buyers will purchase all Hologic shares in circulation for $76 apiece. The transaction will be paid in cash. If the company reaches certain revenue indicators, shareholders will be able to receive up to $3 per share. The deal is expected to close in the first half of 2026.^[2]

2021

Purchase of diagnostic systems developer Mobidiag for $795 million

In early April 2021, Hologic acquired diagnostic systems developer Mobidiag for $795 million. The company did not disclose the detailed parameters of the transaction. Read more here.

Purchase of breast cancer molecular diagnostic test developer Biotheranostics

In early January 2021, Hologic announced the acquisition of Biotheranostics for $230 million. The deal is expected to close in February 2021. Her detailed conditions were not disclosed. Read more here.

Purchase of breast biopsy technology developer Somatex Medical Technologies

In early January 2021, Hologic acquired Somatex Medical Technologies, which specializes in biopsy site markers and localization technologies. The acquisition is estimated at about $64 million and includes the Somatex Tumark line of fabric markers, for which Hologic has already acted as a distributor in the United States. Read more here.

2020: Purchase of fibroids developer Acessa Health

In late August 2020, Hologic announced its acquisition of Acessa Health fibroid treatment company for about $80 million. Acessa ProVu system to complement MyoSure products Hologic for Hysteroscopic Removal uterine fibroids. Read more here.

2019: $85 million purchase of ultrasound device maker SuperSonic Imagine

At the end of June 2019, Hologic announced the acquisition of the manufacturer of ultrasound devices SuperSonic Imagine for $85 million. Read more here.

2018: Purchase of oncosurgical device developer Focal Therapeutics

On September 27, 2018, Hologic signed an agreement to acquire oncosurgical device developer Focal Therapeutics for $125 million. The deal will close in early October. Read more here.